top of page

SF Healthcare Week: The CEO of Ionis talks about over 30 years of developing RNA therapies, and a new chapter as a commercial forward company

Jan 15

Brett Monia discusses the approval of TRYNGOLZA and an important data readout this year in severe hypertriglyceridemia. Plus, the potential approval of donidalorsen for hereditary angioedema, how eplontersen is competing in the transthyretin space, and more.

Recent Posts

Australia based Aravax, which is using a peptide based approach to food allergy treatments with the goal of avoiding inflammation, is building out late stage manufacturing capabilities in Oxford, UK

Australia based Aravax, which is using a peptide based approach to food allergy treatments with the goal of avoiding inflammation, is building out late stage manufacturing capabilities in Oxford, UK

Oxford based Theolytics is leveraging a library of 100M variants of adenoviruses for a bottom up approach to oncolytic virus cancer drug development

Oxford based Theolytics is leveraging a library of 100M variants of adenoviruses for a bottom up approach to oncolytic virus cancer drug development

With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space

With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

Visit Savills' Life Sciences Overview

bottom of page